eBook: Advancing Autologous Cell Therapies — Collaboration is Key

The promise of autologous cell therapies is sometimes overshadowed by problems such as high manufacturing costs, scalability concerns, and an overall lack of infrastructure that enables easy access for patients. Such concerns have led investors toward allogeneic alternatives, which seek to alleviate some of those difficulties by providing a cheaper off-the-shelf solution. Unfortunately, allogeneic therapies have a downside, having shown less clinical success than existing autologous therapies.

Jason Bock, chief executive officer (CEO) and cofounder of the Cell Therapy Manufacturing Center (CTMC) discusses how autologous-therapy developers and manufacturers can bring back investors by collaborating with industry stakeholders and committing to technological innovation. For the blueprint, they can learn from the history of monoclonal antibodies (mAbs). Developers of those once-nascent therapies turned a struggling modality into a success story through technology improvements, but they did so slowly and while working in isolation. Through collaboration, developers can improve efficiencies faster, and they can bring autologous cell therapies to more patients and save more lives.

Organizations already are working to optimize media formulations, enhance cell yield, and refine their downstream processing techniques to improve purity and reduce costs. Progress may be inevitable, but the speed of that progress can improve if developers work together for the good of the industry.

Read the complete eBook to discover how autologous cell therapies can improve their trajectory, reach their potential, and save more lives.

Register or Login and hit Download to get the full eBook.